S002 Pearls: Diagnostic and Therapeutic
DESCRIPTION
Faculty will share innovative approaches to a variety of common and perhaps less common conditions. We will present a number of new cases, new diagnostic approaches, surgical pearls, perhaps some older and forgotten approaches to frustrating conditions, aspects of regenerative medicine, and especially, off-label recommendations. Interesting approaches to dermoscopic diagnoses will also be presented. Attendees are encouraged to email challenging cases or favorite off-label pearls to drspstone@gmail.com for inclusion in our discussions.
LEARNING OBJECTIVES
Use innovative therapies for patients with complicated conditions, or common maladies unresponsive to commonly effective approaches.
Safely and effectively utilize established medications for off label uses.
Diagnose lesions with dermoscopy and appropriately communicate with the pathologist.
SCHEDULE
9:00 AM
Introduction
Stephen P. Stone, MD, FAAD
9:05 AM
Clinicopathologic Pearls
Morgan Wilson, MD, FAAD
9:35 AM
Diagnostic and therapeutic pearls.
Mark Lebwohl, MD, FAAD
10:05 AM
Procedural Dermatology Pearls
Rebecca Jean Larson, MD, FAAD
10:35 AM
Dermoscopy clues for diagnosis and management
Aimilios Lallas, MD, MSc, PhD, IFAAD
11:20 AM
Practical Office Pearls
Stephen P. Stone, MD, FAAD
DIRECTOR
Stephen P. Stone, MD, FAAD
SPEAKERS
Aimilios Lallas, MD, MSc, PhD, IFAAD
Rebecca Jean Larson, MD, FAAD
Mark Lebwohl, MD, FAAD
Morgan Wilson, MD, FAAD
HANDOUTS
DISCLOSURES
Aimilios Lallas, MD, MSc, PhD, IFAAD
Avène – Speaker/Faculty Education(Honoraria); Bioderma – Speaker(Honoraria); Elsevier Inc. – Other(Fees); Fotofinder – Advisory Board(Equipment); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(Honoraria);
Rebecca Jean Larson, MD, FAAD
No financial relationships exist with ineligible companies.
Mark Lebwohl, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Added Health – Consultant (1099 relationship)(Honoraria); Aikium – Consultant (1099 relationship)(Honoraria); Almirall – Consultant(Honoraria); AltruBio Inc. – Consultant(Honoraria); Alumis – Consultant (1099 relationship)(Honoraria); Amgen – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Honoraria); Atomwise – Consultant(Honoraria); Avotres, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Bausch Health – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol Myers Squibb – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Cara Therapeutics – Investigator(Grants/Research Funding); Castle Biosciences, Inc – Consultant(Honoraria); Celltrion – Consultant(Honoraria); Clexio Biosciences, Ltd – Investigator(Grants/Research Funding); CoreEvitas, LLC – Consultant(Honoraria); Dermavant Sciences – Consultant(Honoraria), Investigator(Grants/Research Funding); Dermsquared – Consultant (1099 relationship)(Honoraria); Edesa Biotech – Consultant (1099 relationship)(Honoraria); Eli Lilly – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Evommune, Inc. – Consultant(Honoraria); Facilitation of International Dermatology Education – Consultant(Honoraria); Forte Biosciences – Consultant(Honoraria); Galderma – Consultant(Honoraria); Genentech, Inc. – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Inozyme Pharma – Investigator(Grants/Research Funding); J&J Innovative Medicine – Consultant (1099 relationship)(Honoraria); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); Leo Pharma A/S – Consultant(Honoraria); Mayne Pharma Group – Consultant (1099 relationship)(Honoraria); Meiji Seika Pharma Co., Ltd – Consultant(Honoraria); Mindera – Consultant(Honoraria); Mirum Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); New York College of Podiatric Medicine – Speaker/Faculty Education(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Revolo Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Seanergy Maritime Holdings Corp. – Consultant(Honoraria); Strata Skin Sciences – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); Teva Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Trevi Therapeutics – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Consultant(Honoraria);
Stephen P. Stone, MD, FAAD
Abbott Laboratories – Stockholder(Other Financial Benefit); AbbVie – Stockholder Public Company(No Compensation Received); Acuderm, Inc. – Board of Directors(No Compensation Received), Stockholder(No Compensation Received); Becton Dickinson – Stockholder(Other Financial Benefit); Johnson & Johnson Consumer Products Company – Stockholder(Other Financial Benefit); Pfizer Inc. – Stockholder(Other Financial Benefit); Stryker Corporation – Stockholder(Other Financial Benefit);
Morgan Wilson, MD, FAAD
No financial relationships exist with ineligible companies.